Faculty

Institution

Unit

Venue

R. Eric Davis

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Immunology

Department Of Lymphoma And Myeloma

R. Eric Davis is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research integrates immunology, oncology, and pharmacology, focusing on the molecular heterogeneity of lymphoid neoplasia and cancer immunotherapy. His recent work includes developing patient-derived xenograft repositories for large B-cell lymphoma, investigating CD40-responsive enhancer activation in CREBBP-mutant lymphomas, and exploring therapeutic strategies targeting B-cell receptor internalization and EZH2 inhibition in diffuse large B-cell lymphoma. He also studies phosphoinositide-dependent protein kinase 1 as a metabolic regulator in lymphoma. His contributions span clinical trials, such as combining obinutuzumab with lenalidomide for follicular lymphoma, and mechanistic studies on CD8+ T-cell priming.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

R. Eric Davis

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

immunology oncology lymphoid neoplasia hematology cell biology leukemia hematological malignancies cancer research pharmacology tumor biology medicine cancer immunotherapy cancer cells medicinal research oncogenes immunotherapy therapeutic targets cellular therapy cancer biology immune responses cancer treatment molecular cancer anti-cancer agents cancer genetics enzyme inhibition cancer care cell death malignant blood disorders experimental medicine pharmacotherapy myeloid neoplasia cell research stem cell research cancer genomics apoptosis immune checkpoint inhibitors cellular immune responses multiple myeloma hemostasis acute myeloid leukemia signaling pathways molecular cell biology cell transplantation cell regulation cancer immunosurveillance large b-cell lymphoma immunohaematology adaptive immune system gene expression profiling t-regulatory cell lymphatic disease immunologic mechanisms therapeutic efficacy melanoma clinical immunology disease progression immunomodulation follicular lymphoma mesenchymal stromal cells clinical transplantation cell therapy molecular immunology immunological biomarkers pathway analysis oncogenic agent relapsed follicular lymphoma survival outcome bone marrow microenvironment double hit lymphoma proteasome inhibitor sensitivity phase ii study immune signatures distinct types mutation genotype gene expression phenotype molecular subtypes

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Patient Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-Cell Lymphoma. bioRxiv (Cold Spring Harbor Laboratory) (2026)

immunologyhematological malignanciesxenograft repositoryhematologycancer researchadult t-cell leukemia-lymphomalymphoid neoplasiamolecular diagnosticsoncologymolecular heterogeneitylarge b-cell lymphomacancer cellspathologytumor biology

174 | Phosphoinositide Dependent Protein Kinase 1 is a Key Metabolic Regulator and Potential Therapeutic Target in Lymphoma. Hematological Oncology (2025)

signaling pathwaysleukemiapharmacologycancer researchcell signalinglymphoid neoplasiaprotein phosphorylationtherapeutic targetscell metabolismoncogenescancer cellssignal transductionpathologytumor biologycell biology

A Phase 2 Study of Obinutuzumab Combined With Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma. Blood Advances (2025)

immunologyhematological malignanciesleukemiahematologylymphoid neoplasiaphase 2oncologypathologygynecologyovarian cancer

Blunted Cd40-Responsive Enhancer Activation in Crebbp -Mutant Lymphomas Can Be Restored by Enforced Cd4 T-Cell Engagement. Blood (2025)

Haopeng YangWenchao ZhangVida RavanmehrGuiling CuiKevin BowmanRuidong ChenJared HendersonShyanne Ruby LockmanEstela RojasAshley Lauren WilsonSydney ParsonsAriel MechalyLeslie RegadAhmed HaouzChristopher R. FlowersSattva S. NeelapuLoretta J. NastoupilRichard Eric DavisQing DengFernando Rodrigues LimaMichael R Green

immunologycrebbp-mutant lymphomaslymphoid neoplasiaimmune responses

Inhibition of Autoantigen-Induced B-Cell Receptor (Bcr) Internalization as a Therapeutic Strategy in Diffuse Large B Cell Lymphoma (Dlbcl). Research Square (2025)

immunologyhematological malignanciesleukemiaautoantigen-induced b-cell receptorlymphoid neoplasiatherapeutic strategytherapeutic targetsimmune responsesautoimmunitypathologycellular therapyimmunotherapycell biology

Long-Term Clinical Outcomes From the Smart Start Trial: Rituximab, Lenalidomide and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Blood (2025)

hematological malignanciesmedicineleukemiasmart start trialhematologylong-term clinical outcomeslymphoid neoplasiaclinical trialsoncologylarge b-cell lymphomajama oncologypathologyimmunotherapy

Multiple Reciprocal Interactions Within B-Cell Receptor and Akt Signaling Pathways Regulate Response to Ezh2 Inhibition in Germinal Center-Derived Diffuse Large B-Cell Lymphoma. Blood (2025)

immunologyhematological malignanciesezh2 inhibitioncell signalinglymphoid neoplasiab-cell receptoroncogenescancer cellsmultiple reciprocal interactionstumor biologycell biology

Mutation of Conserved Mhc Class I Cytoplasmic Tyrosine Affects Cd8+ T Cell Priming, Effector Function, and Memory Response. Frontiers in Immunology (2025)

immunologyconserved mhc classeffector functionmemory responsecellular immune responsescell signalingcell researchimmunological memoryadaptive immune systemimmune responsesimmunity (medicine)cellular therapycell biology

Degradation Trumps Mutations in Cancer. Science (2024)

carcinogenesiscancer geneticscancer researchtumor biologymolecular cancerdegradation trumps mutationssomatic variantoncogenescancer cellsmutagenesis (molecular biology technique)genome instabilitycell biology

Impact of Pik3Ca Gain and Pten Loss on Mantle Cell Lymphoma Biology and Sensitivity to Targeted Therapies. bioRxiv (Cold Spring Harbor Laboratory) (2024)

hematological malignanciespik3ca gainradiation oncologylymphoid neoplasiatumor suppressorstherapeutic targetscellular therapyoncogenescancer cellspten losstumor biologycell biology

1
2
3
4
5
26
10 / page

R. Eric Davis

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Immunology

Department Of Lymphoma And Myeloma

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

R. Eric Davis

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Patient Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-Cell Lymphoma. bioRxiv (Cold Spring Harbor Laboratory) (2026)

174 | Phosphoinositide Dependent Protein Kinase 1 is a Key Metabolic Regulator and Potential Therapeutic Target in Lymphoma. Hematological Oncology (2025)

A Phase 2 Study of Obinutuzumab Combined With Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma. Blood Advances (2025)

immunologyhematological malignanciesleukemiahematologylymphoid neoplasiaphase 2oncologypathologygynecologyovarian cancer

Blunted Cd40-Responsive Enhancer Activation in Crebbp -Mutant Lymphomas Can Be Restored by Enforced Cd4 T-Cell Engagement. Blood (2025)

immunologycrebbp-mutant lymphomaslymphoid neoplasiaimmune responses

Inhibition of Autoantigen-Induced B-Cell Receptor (Bcr) Internalization as a Therapeutic Strategy in Diffuse Large B Cell Lymphoma (Dlbcl). Research Square (2025)

Long-Term Clinical Outcomes From the Smart Start Trial: Rituximab, Lenalidomide and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Blood (2025)

hematological malignanciesmedicineleukemiasmart start trialhematologylong-term clinical outcomeslymphoid neoplasiaclinical trialsoncologylarge b-cell lymphomajama oncologypathologyimmunotherapy

Multiple Reciprocal Interactions Within B-Cell Receptor and Akt Signaling Pathways Regulate Response to Ezh2 Inhibition in Germinal Center-Derived Diffuse Large B-Cell Lymphoma. Blood (2025)

immunologyhematological malignanciesezh2 inhibitioncell signalinglymphoid neoplasiab-cell receptoroncogenescancer cellsmultiple reciprocal interactionstumor biologycell biology

Mutation of Conserved Mhc Class I Cytoplasmic Tyrosine Affects Cd8+ T Cell Priming, Effector Function, and Memory Response. Frontiers in Immunology (2025)

Degradation Trumps Mutations in Cancer. Science (2024)

Impact of Pik3Ca Gain and Pten Loss on Mantle Cell Lymphoma Biology and Sensitivity to Targeted Therapies. bioRxiv (Cold Spring Harbor Laboratory) (2024)

hematological malignanciespik3ca gainradiation oncologylymphoid neoplasiatumor suppressorstherapeutic targetscellular therapyoncogenescancer cellspten losstumor biologycell biology

1
2
3
4
5
26
10 / page